Drug Trial Radar · NCT06581198
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
179
Planned (sponsor's estimate)
Start
Sep 4, 2024
Primary completion
Feb 14, 2028
Study completion Feb 6, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
Conditions
- Lupus Erythematosus, Systemic
- Lupus Nephritis
Interventions
rapcabtagene autoleucelBiological
single infusion of rapcabtagene autoleucel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the efficacy of rapcabtagene autoleucelTime frame: Week 24, Week 52
Locations
107 sites in 26 countries. Site status is shown where the registry gives one.
University Of Alabama
Birmingham, Alabama
Loma Linda University
San Bernardino, California
UCSF
San Francisco, California
Sutter Health Network
San Pablo, California
Ann and Robert H Lurie Childs Hosp
Chicago, Illinois
Northwestern University
Chicago, Illinois
University Of Iowa
Iowa City, Iowa
University of Kentucky
Lexington, Kentucky
Tufts Medical Center
Boston, Massachusetts
Boston Medical Center
Boston, Massachusetts
WA Uni School Of Med
St Louis, Missouri
Duke Clinical Research Institute
Durham, North Carolina
James Cancer Hospital
Columbus, Ohio
Oregon Health Sciences University
Portland, Oregon
Houston Methodist Hospital
Houston, Texas
Univ Of TX MD Anderson CC
Houston, Texas
LDS Hospital
Salt Lake City, Utah
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Curitiba, Paraná, Brazil
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Aarhus N, Denmark
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Clermont-Ferrand, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Paris, France
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.